| Today's Big NewsNov 4, 2022 |
| By Kevin Dunleavy With an FDA approval 19 months ago to treat chronic kidney disease, AstraZeneca’s Farxiga dominated the race against its primary SGLT2 rival—Eli Lilly and Boehringer Ingelheim’s Jardiance. And since then, AZ has reaped the rewards as Farxiga has produced hefty sales increases. But on Friday, Lilly and BI clapped back with data from a CKD trial that they referred to as “landmark." |
|
|
|
By Max Bayer Flagship-founded Repertoire Immune Medicines laid off almost half of its staff more than a year and a half after nabbing $189 million in series B funds. The company is developing a suite of cell therapies targeting cancer, autoimmune and infectious diseases. |
By Robert King A new Senate report found that nine out of 10 states had higher complaints surrounding Medicare Advantage marketing practices from 2020 through 2021, with a key senator calling for CMS to crack down on such practices. |
By Andrea Park NeuroMetrix made headlines—and history—earlier this year as it secured the FDA’s first clearance for a non-drug fibromyalgia treatment and laid out a plan to begin rolling out the wearable neuromodulation device toward the end of the year. |
By Kevin Dunleavy In August at a plant in Perth, Australia, Pfizer had to contend with striking workers over a proposed wage increase that employees found insufficient. Three months later and across the continent in Melbourne, workers at another Pfizer facility have walked out, claiming the company’s proposed wage increases fall far short of the pace of inflation. |
By James Waldron Galapagos is not a company lacking a vision—in fact, they’ve just made their second strategic announcement in six months. This one comes with a further pipeline trim and the loss of 200 roles. |
By Andrea Park For Insulet, this year has been all about the Omnipod 5 insulin pump—and that dedication is already paying off. |
By Frank Diamond Provisions of the Consolidated Appropriations Act that go into effect next year will shift more power and responsibility to self-funded employers. |
By Gabrielle Masson Boehringer Ingelheim has snagged former Novartis leader and Big Pharma vet Lykke Hinsch Gylvin, M.D., to serve as the company’s chief medical officer and head of global medicine. |
By Gabrielle Masson Biomind Labs just hit a landmark on its trip that has clinic flagged as the final destination, posting new data that shows its psychedelic candidate aimed at helping patients with depression is safe and tolerable for healthy individuals. |
By Dave Muoio Hospitals' year-to-date operating margins came in at -0.1% at the end of September as expense reductions couldn't overcome revenue declines, the advisory firm wrote in its latest monthly industry report. |
By Fraiser Kansteiner Credentials for an AstraZeneca internal server were left on the code sharing site GitHub in 2021, where they left sensitive patient data exposed for more than a year, TechCrunch first reported. |
By Max Bayer More than six months after Akebia's anemia med was rejected by the FDA, the company is formally disputing the decision. Akebia expects a response back from regulators before the end of the year. |
Fierce podcastsDon't miss an episode |
| This week on “The Top Line,” we dig into Philips’ revelation that it is laying off 4,000 workers and planning for even more restructuring. |
|
---|
|
|
|
Tuesday, November 8, 2022 | 12:30pm ET / 9:30am PT As a partner in the overall health ecosystem, Myriad Genetics is combining de-identified genetic data with indications, phenotypes, and outcomes to power the next generation of precision medicine advancements. Register now.
|
|
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
VideoRevolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
WhitepaperClarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
WhitepaperLearn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBookOrally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
WhitepaperDid you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|